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Introduction: Advantages of vascular closure device over manual compression include patient comfort,
early mobilisation and discharge, avoidance of interruption of anticoagulation, avoidance of local
compression and its sequelae and less time constraint on staff. No published Indian data exist regarding
Perclose Proglide suture mediated vascular closure device (SMC).
Aim: To study the 24 h and 30 day outcome of Perclose Proglide SMC retrospectively.
Study design: Retrospective observational study conducted in the Department of Cardiology,
Government Medical College, Calicut, Kerala from June 2013 to June 2015.
Methodology: All consecutive patients with Perclose Proglide SMC deployment done by a single operator
for achieving access site haemostasis where 24 h and 30 day post-procedure data were available are
included. Patients were excluded if inclusion criteria were not satisﬁed. Major and minor complications,
procedure success, device failure were predeﬁned.
Results: 323 patients were analysed. Procedure success rate was 99.7% (322/323). Transient oozing
occurred in 44 patients (13.6%), minor and major complications occurred in 2% and 1.5% of patients
respectively. Major complication includes one case of retroperitoneal bleed, one access site infection, one
pseudo aneurysm formation and two access site arterial stenosis. There was no death or complication
requiring limb amputation. ‘‘Preclose’’ technique was used successfully in six patients. Primary device
failure occurred in 12 cases which were tackled successfully with second Proglide in all except one.
Conclusion: Perclose Proglide SMC is a safe and effective method to achieve haemostasis up to 22F with
less complication rate.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Common femoral artery is the most common arterial access site
for percutaneous intervention in our institution, with manual
compression as the most common method to achieve haemostasis.
Although manual compression is the gold standard for achieving the
haemostasis, use of vascular closure devices is becoming popular.
The limitations of manual compression are the need to interrupt
anticoagulation, repeat administration of local anaesthetic, patient’sAbbreviations: PEVAR, percutaneous endovascular aneurysm repair; EVAR, endo-
vascular aneurysm repair; TAVI, trans catheter aortic valve implantation; SMC,
suture mediated closure; VCD, vascular closure device; MRSA, methicillin resistant
Staphylococcus aureus; CFA, common femoral artery; RCT, randomised control trial.
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creativecommons.org/licenses/by-nc-nd/4.0/).discomfort including prolonged recumbency, back pain, urinary
retention and vasovagal reaction. The commonly used vascular
closure devices are either collagen based (Angioseal, Vasoseal) or
suture mediated (Perclose Prostar, Perclose AT, Perclose Proglide).
The advantages of vascular closure devices are better patient
comfort, less stress on staff, less nursing time for post-procedure
monitoring, shorter time for haemostasis, early ambulation and
early hospital discharge. 6F Perclose Proglide suture mediated
closure device (Abbott Vascular Devices, Redwood City, CA, USA) is
the most common vascular closure device used to achieve
haemostasis in our cath lab. Major limitation of Proglide is the
cost of the device. Literature review shows paucity of Indian data.
Studies from abroad may not be applicable to our population and
various published studies show different rates of complications. Our
aim is to retrospectively study the outcome of Perclose Proglide
suture mediated closure device (SMC) in Indian population.ay outcome of Perclose Proglide suture mediated vascular closure
g/10.1016/j.ihj.2016.06.008
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To study the 24 h and 30 day outcome of 6F Perclose Proglide
suture mediated closure device.
3. Methodology
3.1. Study design
Retrospective observational study from the Department of
Cardiology, Government Medical College, Calicut, Kerala, India
during June 2013 to June 2015.
3.2. Inclusion criteria
All patients undergoing percutaneous interventions in whom
Perclose Proglide SMC was deployed to achieve haemostasis by a
single operator, provided their 24 h and 30 day follow-up data
regarding clinical outcome and access site are available.
3.3. Exclusion criteria
If the inclusion criteria are not satisﬁed.
3.4. Data collection
Baseline clinical data and 24 h post-procedure data were
collected from the prospective institutional interventional data-
base. For 30 day’s clinical data, patients were contacted over
telephone and advised to review with the follow-up data card. If
clinical data regarding access site and ipsilateral limb are not
available, patients were interviewed regarding access site symp-
toms or any hospitalisation for access site complication or
ipsilateral claudication during the ﬁrst 30 days after the procedure.
If the patients were admitted for access site complications during
the ﬁrst month post-procedure, their clinical data are collected
from the hospital case record or discharge summary.
4. Perclose Proglide SMC deployment-procedure1
(Supplementary video)
All the deployments were done by a single operator and the
decision to deploy was at the discretion of the operator. Perclose
Proglide SMC is a 6F suture based haemostatic device using
polypropylene suture. The device consists of a plunger, handle,
guide, and knot pusher. All Perclose Proglide insertions were done
after ensuring vascular surgery back up. Pre-insertion ﬂuoroscopy
was used to evaluate local vessel wall calciﬁcation. Antibiotic
prophylaxis was not used for device placement. Periprocedural
antiplatelets and anticoagulants were used in accordance with the
institutional protocol for the respective interventional procedure.
After the percutaneous procedure, under strict aseptic precau-
tion catheter is removed and a 0.035 in. guide wire introduced
through the sheath. Perclose Proglide device is tracked over the
wire. Once the wire exit port of the device reaches the skin surface,
the guide wire is removed and device is further advanced until
pulsatile bleeding appears through the marker lumen side port
which conﬁrms the intravascular positioning. Subsequently the
lever is pulled to deploy the ‘‘feet’’ within the arterial lumen. The
device is gently pulled back to position the feet against the anterior
arterial wall. As the plunger is depressed, two needles are deployed
within the tissue track and directed towards the feet. Further
depression of the plunger, advances the needles through the
arterial wall and into the feet. The feet capture the needles,
creating a suture loop. The device (containing the needles) is then
removed, leaving behind the two suture tails. The longer tail isPlease cite this article in press as: Vinayakumar D, et al. 24 h and 30 d
device: An Indian experience, Indian Heart J. (2016), http://dx.doi.orpulled steadily and preformed knot is pushed towards the
arteriotomy site using the knot pusher provided to achieve
haemostasis. The remaining free suture is then cut just above
the knot using the blade embedded in the knot pusher, and a
suitable dressing is placed on the wound. After the procedure distal
ﬂow is conﬁrmed by examining the distal pulse. Manual
compression is used if bleeding continues after placing the suture.
Patients remained supine for 6 h after the procedure. They are
reassessed at 18–24 h after the procedure for any complication and
if there are no complications, the patients are discharged within
24 h.
5. Preclose technique
Perclose Proglide is used in the ‘‘Preclose’’ manner for large
sized wounds. Wounds up to 14F shall be closed by two preplaced
sutures and above 14F using three pre-placed sutures. For this, a
femoral angiogram of the target vessel is performed after inserting
a 5F/6F pigtail catheter through the opposite femoral artery or an
upper limb artery. The loop of the pigtail catheter is placed at the
target site of puncture with a clear visualisation of the loop ‘‘en
face’’ in PA view. This angiogram is used as the landmark to ensure
the puncture in the centre of the vessel wall anteriorly. Through
the standard 18 gauge puncture needle a 0.035 J guide wire is
introduced over which the ﬁrst Proglide SMC is introduced. Guide
wire is removed, SMC is rotated to 10 o’ clock position and ﬁrst
suture is placed. The 0.035 J guide wire is re introduced through
the wire port over which the second Proglide SMC is introduced.
This SMC is rotated to 2 o’ clock position and the second suture is
placed. A third suture is placed in the 12 o’ clock position by a third
device for >14F wounds. The ﬁnal wire is retained for introducing
the vascular sheath. After placing each suture the respective
threads are carefully kept apart to prevent intertwining with the
subsequently placed suture. A 7F vascular sheath is now
introduced over the retained guide wire. This is followed by
progressively larger dilators to enlarge the wound and ﬁnally the
desired vascular sheath or device is introduced. Progressive
dilatation helps to prevent an uncontrolled tear in the vessel wall.
After completing the intervention procedure, the introduced
vascular sheath or device is removed. Each of the preplaced
sutures is now sequentially closed using the knot pusher. Distal
pulse is examined after closing the wound to ensure the integrity of
the arterial lumen.
6. Deﬁnitions used in the study
6.1. Major complication
Any death or loss of limb due to access site complication or any
access site symptom immediately or within 30 days of Proglide
deployment requiring blood transfusion, antibiotic usage or any
percutaneous or surgical therapy to address the complication.
6.2. Minor complication
Persistent access site pain or bleeding which needed more than
5 min of local arterial compression and not meeting the criteria of
major complication.
6.3. Procedure success
Achievement of complete haemostasis with or without
compression, i.e. use of light, non-arterial compression of less
than 5 min.ay outcome of Perclose Proglide suture mediated vascular closure
g/10.1016/j.ihj.2016.06.008
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Failure to place suture correctly inspite of proper technique and
ﬁnal haemostasis achieved with manual arterial compression.
7. Results
342 Perclose Proglide SMC deployed patients were identiﬁed,
19 were excluded due to various reasons and 323 were accepted
for ﬁnal analysis (Table 4). Baseline characteristics and percutane-
ous procedure details are given in Tables 1 and 2 and Fig. 1.Table 2
Percutaneous procedure details.
Percutaneous procedure
details (N = 323)
Access site CFA: 327 (100%)
Antiplatelet loading dose Aspirin + Clopidogrel: 304 (94%)
Aspirin + Prasugrel: 19 (6%)
Periprocedure antiplatelets Tiroﬁban: 14 (4.3%)
Periprocedure anticoagulation Heparin
10,000 IU: 96 (30%)
7500 IU: 227 (70%)
Sheath size 7F = 316, 11F = 1, 14F = 3,
21F = 1, 22F = 2
Perclose Proglide SMC
deployment technique
Preclose: 6
Postclose: 317
Table 1
Baseline characteristics.
Baseline characteristics (N = 323)
1 Age (years) 36–76 (mean  SD = 55  9)
2 Sex Male: 257 (79.6%)
Female: 66 (20.4%)
3 Diabetes mellitus 137 (42%)
4 Hypertension 126 (39%)
5 Dyslipidemia 131 (40%)
6 Smoking 154 (48%)
7 Chronic kidney disease 0
8 Lower limb peripheral
vascular disease
25 (7.7%)
Fig. 1. Percutaneous procedures for which
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SMC procedure was successful in the ﬁrst attempt in
311 patients. In remaining 12 cases a second device was
successful in all except one in whom haemostasis was achieved
with manual arterial compression for 30 min. Final procedure
success rate was 99.7% (322/323). Immediately after deploy-
ment, 44 (13.6%) patients had mild oozing requiring manual
non-arterial compression of less than 5 min. Oozing is not
considered as a complication as per the deﬁnition. Seven cases
(2%) required 15–20 min of arterial compression. Retroperito-
neal haematoma with haemoglobin drop of 3 g/d1 occurred in a
middle-aged woman (0.3%) and was managed conservatively
with three units of packed cell transfusion. She was discharged
from the hospital after 5 days.
Acute arterial stenosis with slowing of distal ﬂow occurred
during Proglide deployment in one case (supplementary Fig. 3A
and B). The patient was a middle-aged man who underwent PTA
with stenting for aorto iliac disease through bilateral common
femoral (CFA) and left brachial arterial access. Patient complained
of pain over the left leg immediately after suture placement at left
CFA with Proglide SMC. Check angiogram of left CFA through the
brachial access showed acute subtotal occlusion at the Proglide
deployed site and was immediately corrected by balloon dilatation
and stenting as there was a tendency to recoil after plain balloon
dilatation. No mortality or complication requiring amputation
occurred in the ﬁrst 24 h.
Apart from the 24 h outcome, 30 day’s follow-up (Fig. 2B)
showed one diabetic perimenopausal woman who developed
access site MRSA infection 1 week after the procedure. She
subsequently developed pseudoaneurysm of CFA. This was
managed surgically and 3 weeks of parenteral antibiotic therapy.
Another patient developed right lower limb claudication following
Perclose Proglide SMC 2 weeks after the procedure and Doppler
evaluation showed critical stenosis at the site of suture placement
and was managed by balloon angioplasty. There was no mortality
or complication requiring amputation during the 30 days follow-
up. We have used ‘‘Preclose technique’’ in six patients without any
complication during the 24 h or 30 days follow-up. Overall
outcome of Perclose Proglide SMC, their complications and
management are summarised in Table 3. Perclose Proglide deployment done.
ay outcome of Perclose Proglide suture mediated vascular closure
g/10.1016/j.ihj.2016.06.008
Fig. 2. (A and B) 24 h and 30 day outcomes of Perclose Proglide SMC.
Table 3
Outcome of Perclose Proglide SMC.
Results
Outcome of Perclose Proglide SMC Treatment given
Minor complication
Minor bleeding 7 (2%) Compression
Major complication 5 (1.5%)
Major Bleeding 1 (0.3%) Blood transfusion
Pseudo aneurysm 1 (0.3%) Surgical correction
Local infection 1 (0.3%) IV antibiotics followed by surgical correction as complicated by pseudo aneurysm
Arterial occlusion 2 (0.6%) Balloon dilatation with stenting in ﬁrst case
Balloon dilatation only in other case
Others
Primary device failure 12 (3.7%) Eleven case managed with second device
Complete device failure 1 (0.3%) Manual compression
Oozing 44 (13.6%) Non-arterial compression
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Table 4
Selection of study population.
 
 N= 342  
(10 Paents baseline data wer e missing)  
 
 N= 332  
(9 Paents lo st 30 day foll ow up ) 
 N=323  (No:  for paents for ﬁnal  analysis) 
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There is paucity of Indian data regarding the use of vascular
closure devices. We attempted to assess the 24 h and 30 days
outcome of suture mediated closure device, the ‘‘Perclose Proglide’’
(Abbott Vascular Devices, Redwood City, CA, USA) SMC. The
operator has used Perclose Proglide in 22% of the cases during the
study period. The device could be effectively used in both preclose
manner for 14F and larger arteriotomies and in post-close manner
for up to 11F arteriotomies with high procedural success (99.7%),
low complication rates and no mortality or limb loss. Although
SMC devices have not established superiority over manual
compression in small wounds there are certain distinct advan-
tages. In large wounds as in EVAR, Aortic Valvotomy and TAVI they
serve a long way in reducing the need for open surgical arteriotomy
and its ensuing morbidity and cost involved in employing the
surgical team.
Vascular closure devices are classiﬁed in to passive and active
devices. Passive devices include haemostatic pads (Chitoseal,
Neptune pads) and Compression devices (Femostop). Active
devices include collagen based (Vasoseal, Angioseal), Clip based
(StarClose) or Suture based devices (Perclose Proglide, Prostar, X-
Site, Super Stitch). Suture mediated vascular closure devices
deploy sutures to achieve haemostasis with a knot made either by
an in built device mechanism or manually which is advanced
towards the puncture site to achieve closure of arteriotomy.
The Perclose system (Perclose Inc., Redwood City, CA, USA)
introduced in 1994 was the ﬁrst suture-mediated device to be
approved by the FDA. Subsequently various designs were
developed like Perclose AT, Prostar XL, Closer S and Proglide.
Perclose Proglide introduced in 2004 is the latest generation suture
mediated device from Abbot Vascular devices and FDA approved
this device in 2013. Perclose Proglide offers improvements in the
ease of knot delivery, trimming of the suture and polypropylene
monoﬁlaments sutures which are non-inﬂammatory and with
high tensile strength. Each type of device is meant for a particularly
sized2 arteriotomy wound like X-SITE for 6F, Super Stitch for 6–8F,
Perclose AT for 5–8F, Prostar for 8–10F and Proglide for 5–21F
sheath sizes. For Perclose Proglide, recommendation is to use two
or more devices in a ‘‘preclosure’’1 manner if puncture size 8F.
Older generation SMCs deploy needle from inside the vessels
and are associated with vascular complications and involves
complex steps for knot making and its advancement towards the
site. Advantages of newer devices are needle deployment from
outside the vessel, automated knot forming mechanism, inbuilt
quick cut suture trimming mechanism, and easy knot advance-
ment towards the arterial wound.
Steps involved in the Proglide SMC deployment are positioning
the device, needle deployment, suture capture, needle removal,
knot advancement and trimming of the excess thread. Each stepPlease cite this article in press as: Vinayakumar D, et al. 24 h and 30 d
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if not properly trained. Studies have documented a ‘‘learning
curve’’ phenomenon with vascular closure devices (VCD)3,4
especially with SMC. Balzer et al.4 showed that the learning curve
for technical success with suture-based closure was steeper and
longer (>350 patients).
Although there are no contraindications for the use of Perclose
Proglide SMC, manufacturer has mentioned certain patient groups
in which safety and effectiveness has not been established.2 These
includes small femoral arteries (<5 mm), access site above the
most inferior border of inferior epigastric artery, Non-CFA access
site, ﬂuroscopically visible CFA calciﬁcation, anterograde punctu-
res, morbid obesity, access site in vascular graft, posterior wall
puncture and multiple punctures.5
Complications6 noted during the arterial closure include
infection, bleeding both minor and major, pseudoaneurysm,
arterial laceration, arteriovenous ﬁstula, embolisation, limb
ischaemia, femoral artery thrombosis or dissection, access site
pain, nerve injury and death. Review of literature shows that the
rate of major complications varies from 3% to 4.6% with Perclose
SMC7,8 and 1.5–9% with manual compression.9,10 Our study had a
procedure success rate of 99.7% (322/323), major complication rate
of 1.5% and minor complication rate of 2% (Table 3). If Puncture size
is 8F, two or more devices1 are recommended by the
manufacturer in a preclose manner. But in our series in one case
it was able to close successfully a 11F size arterial puncture with a
single Proglide device which was deployed after the percutaneous
procedure. ‘‘Preclose’’ technique with two devices was used in
wound sizes up to 14F and three devices in >14F puncture wound.
‘‘Preclose technique’’ was successfully used in 6 patients to achieve
complete haemostasis without any complication.
The reasons for device failure in the study were that in two
cases knot came out along with the device when the device was
attempted to be removed and knot could not be repositioned by
pulling the thread. In other cases when plunger was retracted, the
threads were found to be detached from the plunger and knot
could not be made. These problems could be noticed while the
device is still inside the arterial lumen. In these cases 0.035 J wire
was reintroduced through the wire port and failed device replaced
with a second one and successful suture placement accomplished.
In one case second device also failed and ﬁnal hemostasis was
achieved with manual compression. Other causes of device
failure11 described in the literature include artery getting split
at the site of device entry, failure to deploy needle due to vessel
calciﬁcation,7,12–15 failure to approximate the arteriotomy wound
or failure to form or deliver the knot. Mechanism of the two access
site artery stenosis in our series remain unclear. It may be due to
the posterior wall getting caught by the foot plate or an
inadequate longitudinal alignment of the device feet inside the
arterial lumen due to tilt or rotation of device. Other described
causes in literature are intraluminal atheroma being snared
causing luminal obstruction16 and acute thrombosis at the access
site. Thrombosis17 occurs if device is advanced too far within the
artery and the foot plate is dragged against the posterior arterial
wall. Infection rate in our study was low even though antibiotic
prophylaxis was not used.
Review of literature showed varied results with the use of
suture mediated closure system (Table 5, Supplementary Data) and
there is no Indian data available regarding Perclose Proglide SMC.
Chamberlin et al.18 have showed a device failure rate of 14.3%,
retroperitoneal bleed of 1.8% and zero infections with the use of
Perclose SMC. Quinn et al.19 showed that Perclose Prostar SMC was
associated with device failure rate of 4%, acute femoro popliteal
thrombosis in 1%, pseudoaneurysm in 5%, need for additional
manual compression in 2%, infection rate of 1% and asymptomatic
intimal dissection ﬂap in 1%. Wagner et al.8 in their study withay outcome of Perclose Proglide suture mediated vascular closure
g/10.1016/j.ihj.2016.06.008
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major complication rate of 4% and 3% respectively. Duda et al.20
achieved technical success in 97.5% with minor complication of 6%
with the use of Techstar and Prostar Plus SMC. Bilge et al.21
reported a procedural success and device failure of 98.8% and 1.2%
with single Proglide and 94.2% and 5.8% with double Proglide use
respectively. Mackrell et al.22 showed 95% success rate and major
complications of 1.4% with the use of Perclose SMC. PEVAR trial,23
in which Perclose Proglide was used in a ‘‘preclose’’ manner for
achieving hemostasis after percutaneous endovascular aortic
repair showed a major complication rate of 6% and a device
failure rate of 6%.
8.1. Limitations
This was a retrospective observational study. A control group
was not employed. It was conducted in a single centre and by a
single operator. Results may vary with the experience of the centre
and operator, as a learning curve phenomenon has been reported
by some authors. Real world analysis of cost involved could not be
done as it was conducted in a Government institution where
services both medical and nursing are offered without a price.
9. Conclusion
Perclose Proglide SMC is a safe and effective option for closure
of up to 22F puncture size arteriotomy wound in Indian
population. The operator was successful in closing an arteriotomy
wound of 11F size with single Proglide deployed after the
procedure, but this cannot be recommended as a standard practice
until validated in bigger samples. ‘‘Preclose’’ technique with two
devices were used successfully in arteriotomy size of 14F and with
three devices if arteriotomy wound is >14F and is found to be a
safe and effective option for Indian population as well. Our study
showed low complication rates with Perclose Proglide SMC if
properly deployed. As compared with the major complication rates
of manual compression7,8 mentioned in the literature, our results
also showed comparably low rates. However large scale RCTs
comparing manual compression and Perclose Proglide SMC may be
needed to assess the actual advantage of one method over the
other. Major limiting factor for the use of Perclose Proglide SMC in
Indian scenario is cost of the device. But this can be negated by a
shorter hospital stay and reduced man power utilisation as
compared with manual compression. Cost analysis also needs a
large scale RCT. Successful closure of arteriotomy wounds of up to
22F indicate the feasibility of percutaneous closure in large
arteriotomy wounds as required in EVAR and TAVI. This clearly
helps to reduce the need for open arteriotomy and the ensuing
morbidity and additional cost and offers a distinct advantage over
open surgical arteriotomy.
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